Aziyo Biologics, Inc. announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. Colpman was the managing partner of Colpman Consulting Ltd., a business development consultancy, from July 2014 to March 2020.

Prior to this, he was a senior vice president at Shire Plc from 1999 to 2014. Prior to Shire Plc, Colpman had senior roles in business development at Novo Nordisk A/S, Glaxo Wellcome Plc and Boots Pharmaceuticals Ltd. Colpman currently serves on the board of OakHill Bio, a private clinical-stage neonatology and rare disease therapeutics company. In addition, he is currently an advisor to HighCape Capital, an affiliate of HighCape Partners, which is an investment fund and a controlling stockholder of the Company.

Colpman received a B.Sc. from Portsmouth University in the field of pharmacy.